Active ingredient: methylphenidate hydrochloride · UK formulations: Medikinet (IR tablet) · Medikinet XL (bimodal capsule) · Equasym XL (equivalent bimodal capsule)
Medikinet is one of two UK methylphenidate brands sold in both immediate-release and bimodal-release formulations. Useful flexibility for adults whose dosing needs do not fit a single long-acting profile.
Tap a tab to see how each formulation differs. Same molecule, very different daily shape.
The IR tablet enters the bloodstream directly. Onset within thirty to sixty minutes, peak around two hours, clears within four. Taken two or three times daily depending on the prescribed schedule.
Medikinet XL uses a 50/50 split of immediate-release and extended-release beads inside a single capsule. The result is two peaks of activity through the day. Useful for adults whose energy curve does not match a smooth long-acting profile.
Medikinet is methylphenidate. The same active molecule as Ritalin, Concerta XL, Equasym XL and the rest of the methylphenidate family. What makes Medikinet distinct is that the brand sells in both an immediate-release tablet and a bimodal-release capsule (Medikinet XL), giving prescribers flexibility within one brand.
The IR tablet works like any short-acting methylphenidate. Onset within thirty to sixty minutes, peak around two hours, clears within four. Useful as a top-up alongside long-acting formulations or as the primary medication for adults who prefer fine-grained dose control.
Medikinet XL is a once-daily capsule that uses a 50/50 mix of immediate and extended-release beads. The first half releases on contact, the second half releases approximately three to four hours later. The result is a two-peak profile across roughly six to eight hours of effective coverage. Equasym XL uses the same mechanism and is therapeutically equivalent.
Same active molecule, different release profiles. Pick the one that fits your day.
Medikinet IR works well for adults who want fine-grained control over when their medication is active, who use it as a top-up alongside a long-acting morning dose, or who responded poorly to long-acting formulations. The trade-off is multiple daily administrations.
Medikinet XL works well for adults who want a single morning dose, especially those who experience a mid-morning slump on a smooth long-acting formulation like Concerta XL. The two-peak profile from a 50/50 bead split can produce a different felt experience.
Some prescriptions combine Medikinet XL in the morning with a Medikinet IR top-up in the afternoon. ADHDose models the combination correctly, treating each dose with its own release profile and stitching them into one continuous picture.
Medikinet IR: 5mg, 10mg, 20mg. Medikinet XL: 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg.
ADHDose recognises Medikinet IR and Medikinet XL as separate formulations and models each correctly. The bimodal release in XL is rendered with two peaks; the IR is rendered as a sharp short release. Combination prescriptions are stitched into one timeline. The Clinician Summary export pulls 28 days of dose-time and response data into NHS prescriber format for review appointments.
Medikinet IR and Medikinet XL behave differently across the day. ADHDose models each formulation correctly and combines them when you take both.
ADHDose recognises Medikinet IR, Medikinet XL and the equivalent bimodal Equasym XL. Each is modelled with the right release profile, calibrated to your dose and timing.
Most people tolerate Methylphenidate well, especially after the first few weeks. Here are the patterns worth noticing — and the ones that warrant a call to your prescriber.
Most ease in the first two to four weeks. Logging them daily helps you and your prescriber decide whether they are settling or sticking.
Not emergencies, but worth bringing up. ADHDose tags recurring patterns automatically in your daily logs.
Rare, but worth knowing. If you see any of these, contact your prescriber rather than stopping on your own.
The first weeks of Methylphenidate have a recognisable shape. Knowing what is normal at each stage stops you reading too much into a single bad day.
Most people feel something within the first hour of the first dose. The first few days often involve small wobbles — appetite changes, sleep shifts, occasional headaches. None of this is unusual. Daily logging helps separate first-dose nerves from real side effect patterns.
Side effects from days one to three usually start to ease. The dose-response becomes more predictable. Track focus, sleep and energy daily. This is the data your prescriber wants at your first review.
Most UK and US protocols schedule the first review around week two or four. Your prescriber will ask about effect, side effects, sleep and appetite. Bringing tracked data — rather than relying on memory — turns the review from vague impressions into something concrete.
If the first dose is not quite right, your prescriber will adjust upward in defined steps. Each step is usually held for two to four weeks before the next adjustment. The same daily logging continues.
Once the dose is settled, reviews shift to every six to twelve months. Daily logging becomes lighter — focus and sleep are usually enough. The Clinician Summary export gives prescribers a 28-day window of evidence at each review.
ADHDose makes the milestone view concrete. Daily logs of focus, sleep, energy and side effects across the titration window show the trajectory clearly — to you, and to your prescriber when review day arrives.